New Ask Claude or ChatGPT about any stock, using Bullpen. Bullpen in Claude or ChatGPT. 7 days free

Wednesday, November 18, 2026

Back to the front page

From X

Kevin Mak on X

$CMPS Some questions about the CNPV program being shelved and how it will affect Compass' application. The honest answer is "nobody knows", though FDA has said on the record that career staff are still reviewing applications that already hold a voucher (a bit vague!). My hope is that they continue the existing process. CMPS (and Usona) have been on a rolling submission, so there is an established workflow to "keep the ball moving". See the transcript below for a sense of the relationship they've built with the FDA over the past months. Also, my guess is that 30-70% (yes, wide range) of the review is already "done", so FDA isn't starting from scratch as of the Nov 9th submission date. Even if they reallocate resources and "slow things down", I could see a plausible slowdown case where it takes 3-4 months (instead of 1-2 months on a full CNPV program, but not the 8-12 months of the regular non-CNPV track). Disclosure: Creek Drive and its affiliated funds holds a long position in CMPS. Views expressed are current opinions for information only, subject to change and are not investment advice or a recommendation to buy or sell any security. Investing involves the risk of loss and past performance is not indicative of future performance. See the disclosures link in my bio for more important information. -- Related/unrelated, the "race" between Usona and Compass is actually kind of moot. The actual "approval effective date" will likely be the DEA rescheduling date. Once the FDA gives the nod to EITHER drug, that starts the process on DEA rescheduling (which people are guessing will take around 90 days).

Monte Investments Market Brief Vol. CXXXVI

Monte Investments rotated Nvidia into Alphabet before earnings and reviews Knife River’s margin squeeze, AMD’s World Labs acquisition, and…

Envisioning Entravision

Entravision’s AdTech revenue rose 133% and EBIT 261% in Q3 as management weighs TV-station sales before its TelevisaUnivision agreement…

Bimergen Energy: Research Note

Bimergen Energy reported $3.0 million of Q3 revenue, below estimates, while a $3.6 million fair-value gain lifted net income to $2.4…

Trading Post November 16, 2026

Adobe (ADBE) became a full position at about $246, backed by buybacks and confidence it can adapt to AI competition.

TOST · long

Toast INC

Toast is pitched as a long opportunity on its growth runway and margin expansion after recent software and payments underperformance.

003100.KQ: grain share 25% to 38%

Sun Kwang (003100.KQ) raised grain market share from 25% to 38% as its founding family transferred 24% of the company to holding companies…

Floor & Decor: Still Waiting

Floor & Decor has logged 20 straight quarters of comp transaction declines, with Q3 quarter-to-date same-store sales down about 3.8% as…

Publications we follow

Every publication on this site, hand-picked.

130 publications

Newsletters 110

X accounts we follow

Every account on this site, hand-picked.

91 accounts

Investor letters we follow

383 firms

Sectors

Ordered by how often our editor reaches for them.